All In Biotech

Drug Trial Radar · NCT06687382

Clinical Trial With MBK-01, Intestinal Microbiota Capsules, for the Treatment of Patients With Recurrent Diverticulitis

A Phase IIa Randomized, Controlled, Open-label Clinical Trial to Assess the Efficacy, Safety, and Tolerability of the Investigational Medicinal Product MBK-01, FSPIM (Full Spectrum & Purified Intestinal Microbiota) Oral Capsules, as Well as to Determine the Optimal Dosage in the Treatment of Patients With Recurrent Diverticulitis (DIREBIOT)

Last checked: Nov 19, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Apr 3, 2025

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Sponsor type
Industry
First posted
Nov 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with diverticulitis experience a prolonged course of the disease and report a variety of physical, psychological and social symptoms, which highly impacts in their quality of life. Although antibiotic therapy has been the preferred treatment option for acute diverticulitis, it does not control the disease in 40 percent of the patients with complicated diverticulitis and 13 to 23 percent of the patients with non-complicated diverticulitis, which results in chronic and recurrent episodes of diverticulitis. As the episodes repeat, the outpatient conservative treatment has worse success rates and the incidence of complicated diverticulitis with abscess increases up to five times. Therefore, it is of great importance to establish new treatments in order to avoid the recurrences of the disease. As of today, there is not enough evidence of the efficacy of current treatment options to prevent recurrences in patients with diverticulitis, but recent approaches suggest the modification of intestinal microbiota as a preventive strategy. Microbial imbalance (dysbiosis) has been proposed as a mechanism involved in the transition from diverticulosis to diverticulitis, inflammation and some of the symptoms of the disease. In this way, fecal microbiota transplantation (FMT) could have an important role in the prevention of new episodes, as it can modify the composition of the intestinal microbiota in a less invasive and more physiological way. Until now the efficacy of FMT in patients with recurrent diverticulitis has not been assessed; however, its benefits and safety have been demonstrated in studies for inflammatory bowel disease (IBD), a pathology with similarities to diverticulitis in its symptoms and underlying inflammation. The objective of the present clinical trial is to assess the efficacy of MBK-01 (heterologous lyophilized intestinal microbiota oral capsules) in reducing the frequency of episodes in recurrent diverticulitis, its safety and tolerability and to determine the optimal dosing regimen.

Conditions

  • Diverticulitis
  • Diverticulitis of Sigmoid

Interventions

  • MBK-01Biological

    Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule during 16 days. Participants will receive a total dose of 20 capsules of MBK-01.

  • MBK-01Biological

    Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule for 16 days and a maintenance dose 3 months after the ending of the initial dose. The maintenance dose is administered the same as the initial dose: 4 capsules of MBK-01 orally the first day, followed by a single daily capsule for 16 days. Participants will receive a total dose of 40 capsules of MBK-01.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of new episodes of acute diverticulitis during the trialTime frame: Up to 1 year after the start of the treatment
  2. Time to first episode of acute diverticulitisTime frame: Up to 1 year after the start of the treatment
  3. Time to successive episodes of acute diverticulitis (other than the first episode)Time frame: Up to 1 year after the start of the treatment
  4. Time between episodes of acute diverticulitisTime frame: Up to 1 year after the start of the treatment
  5. Number of hospitalizations due to acute diverticulitis in the trialTime frame: Up to 1 year after the start of the treatment
  6. Number courses of systemic antibiotic treatment used in the trial for the episodes of acute diverticulitisTime frame: Up to 1 year after the start of the treatment
  7. Need for surgery for acute diverticulitis during the trialTime frame: Up to 1 year after the start of the treatment
  8. Occurrence of Adverse Events (AES)Time frame: Up to 1 year after the start of the treatment
  9. Occurrence of Serious Adverse Events (SAES)Time frame: Up to 1 year after the start of the treatment
  10. Occurrence of AES that result in discontinuation of study treatmentTime frame: Up to 1 year after the start of the treatment
  11. Occurrence of AES of special interest (AESI)Time frame: Up to 1 year after the start of the treatment
  12. Occurrence of diverticulitis-related AESTime frame: Up to 1 year after the start of the treatment
  13. Changes in vital signsTime frame: Up to 1 year after the start of the treatment
  14. Changes in laboratory valuesTime frame: Up to 1 year after the start of the treatment
  15. Number of new episodes of acute diverticulitis in the trial between the two MBK-01 regimensTime frame: Up to 1 year after the start of the treatment
  16. Occurrence of treatment-related AES between the two MBK-01 regimens during the trialTime frame: Up to 1 year after the start of the treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.